|Exchange (%)||(US Dollar)|
|52 Week High|
|52 Week Low|
|Data as of|
Copyright Nasdaq. Minimum 15 minutes delayed.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.